Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (6): 1071-1077. doi: 10.19723/j.issn.1671-167X.2019.06.017

• 论著 • 上一篇    下一篇

18F-FDG PET/CT联合多种肿瘤标志物在结直肠中分化腺癌术后复发及转移中的应用价值

张旭初,张建华,王荣福(),范岩,付占立,闫平,赵光宇,白艳霞   

  1. 北京大学第一医院核医学科,北京 100034
  • 收稿日期:2017-10-24 出版日期:2019-12-18 发布日期:2019-12-19
  • 通讯作者: 王荣福 E-mail:rongfu_wang@163.com

Diagnostic value of 18F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma

Xu-chu ZHANG,Jian-hua ZHANG,Rong-fu WANG(),Yan FAN,Zhan-li FU,Ping YAN,Guang-yu ZHAO,Yan-xia BAI   

  1. Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
  • Received:2017-10-24 Online:2019-12-18 Published:2019-12-19
  • Contact: Rong-fu WANG E-mail:rongfu_wang@163.com

RICH HTML

   

PDF (PC)

摘要：

目的 探讨18F-FDG PET/CT与肿瘤标志物(CEA、CA19-9、CA24-2)在结直肠中分化腺癌患者术后探测及提示复发和转移灶中的应用。方法 对55例结直肠中分化腺癌患者进行 18F-FDG PET/CT显像及肿瘤标志物筛查,并与病理及临床随访结果进行比较。结果 对18F-FDG PET/CT对于结直肠中分化腺癌术后复发及转移灶的诊断效能为:灵敏度95.74%(45/47),特异性75.00%(6/8),阳性预测值95.74%(45/47),阴性预测值75.00%(6/8),准确率92.73%(51/55),其中假阳性2例,假阴性2例。CEA组、CA19-9组、CA24-2组及肿瘤标记物联合组灵敏度分别为68.09%(32/47)、28.57%(12/42)、40.00%(16/40)及74.47%(35/47),特异性为50.00%(4/8)、66.67%(4/6)、71.73%(5/7)及50.00%(4/8),阳性预测值为88.89%(32/36)、85.71%(12/14)、88.89%(16/18)及89.74%(35/39),阴性预测值为26.67%(4/19)、11.42%(4/34)、17.24%(5/29)及25.00%(4/16),准确率为65.45%(36/55)、32.65%(16/49)、44.68%(21/47)及70.91%(39/55)结论 18F-FDG PET/CT对于结直肠癌术后中分化腺癌患者复发及转移灶的探测具有较高的灵敏度及特异性,各项肿瘤标志物对病灶转移及复发均有一定的提示作用,多项肿瘤标志物联合应用更准确。

关键词: 结直肠肿瘤, 正电子发射断层显像计算机体层摄影术, 生物标记, 肿瘤, 肿瘤复发, 局部, 肿瘤转移

Abstract:

Objective: To evaluate the diagnostic value of 18F-FDG PET/CT and tumor markers (CEA,CA19-9,CA24-2) in detection for recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma.Methods: Fifty-five patients were enrolled in this study. All of the patients were tested with serum CEA within 2 weeks when they underwent 18F-FDG PET/CT scan, and some patients were tested with serum CA19-9 and CA24-2 simultaneously. According to the pathology and clinical results of their follow-up, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET/CT and tumor markers were calculated based on different divided groups, respectively.Results: According to the pathology and the results of their clinical follow-up, the sensitivity of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 95.74%, 68.09%, 28.57%, 40.00% and 74.47%, respectively. The specificity of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 75.00%, 50.00%, 66.67%, 71.43% and 50.00%, respectively. The positive predictive value of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 95.74%, 88.89%, 85.71%, 88.89% and 89.74%, respectively. The negative predictive value of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 75.00%, 26.67%, 11.42%, 17.24%, 25.00%, respectively. The accuracy of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 92.73%, 65.47%, 32.65%, 44.68% and 70.91%, respectively. There were 2 cases of false positive and 2 cases of false negative in 18F-FDG PET/CT.Conclusion: 18F-FDG PET/CT has high value in detecting recurrence and metastasis of postoperative colorectal carcinoma. Tumor markers have the positive value to imply the recurrence and metastasis of postoperative colorectal carcinoma and are useful to indicate when to perform the 18F-FDG PET/CT. The combination of tumor markers could improve the diagnostic efficiency to some extent.

Key words: Colorectal neoplasms, Positron emission tomography computed tomography, Biomarkers, tumor, Neoplasm recurrence, local, Neoplasm metastasis

中图分类号: 

  • R735.5

表1

PET/CT、病理及各肿瘤标记物组结果"

PET/CT Pathology CEA (n=55) CA19-9 (n=49) CA24-2 (n=47) Combination of tumor markers (n=55)
Elevated Normal Elevated Normal Elevated Normal Elevated Normal
Positive Positive 30 15 12 28 16 22 33 12
Positive Negative 1 1 1 1 1 1 1 1
Negative Negative 3 3 1 4 1 4 3 3
Negative Positive 2 0 0 2 0 2 2 0

表2

PET/CT及各项肿瘤标志物发现结直肠中分化腺癌术后复发及转移灶的诊断效能"

Testing items Sensitivity Specificity PPV NPV Accuracy
PET/CT (n=55) 95.74 75.00 95.74 75.00 92.73
CEA (n=55) 68.09 50.00 88.89 26.67 65.45
CA19-9 (n=49) 28.57 66.67 85.71 11.42 32.65
CA24-2 (n=47) 40.00 71.43 88.89 17.24 44.68
Combination of tumor markers (n=55) 74.47 50.00 89.74 25.00 70.91

表3

PET/CT在各肿瘤标志物升高和正常组发现结直肠中分化腺癌术后复发及转移灶的诊断效能"

Group Sensitivity Specificity PPV NPV Accuracy
Elevated CEA (n=36) 93.75 75.00 96.77 60.00 91.67
Normal CEA (n=19) 100.00 75.00 93.75 100.00 94.74
Elevated CA19-9 (n=14) 100.00 50.00 92.31 100.00 92.86
Normal CA19-9 (n=35) 93.33 80.00 96.55 66.67 91.43
Elevated CA24-2 (n=18) 100.00 50.00 94.12 100.00 94.44
Normal CA24-2 (n=29) 91.67 80.00 95.56 66.67 89.66
Elevated tumor markers (n=39) 94.29 75.00 97.06 60.00 92.31
Normal tumor markers (n=16) 100.00 75.00 92.31 100.00 93.75

图1

直肠癌术后,可见右侧髂内动脉旁肿大淋巴结,各项肿瘤标志物均正常(CEA 1.86 μg/L、CA19-9 24.93 U/mL、CA24-2 18.13 U/mL)"

图2

右半结肠癌术后,PET/CT显像提示右侧附件区囊实性病灶,葡萄糖代谢增高,CEA 5.83 μg/L、CA19-9<0.60 U/mL、CA24-2 5.3 U/mL"

[1] 吴菲, 林国桢, 张晋昕 . 我国恶性肿瘤发病现状及趋势[J]. 中国肿瘤, 2012,21(2):81-85.
[2] 阮丽琴, 李太原, 周凤凤 . 不同年龄组的结直肠癌临床流行病学分析[J]. 实用临床医学, 2016,17(4):86-87.
[3] 张小龙, 高枫, 陈利生 , 等. 结直肠癌病理组织学类型分析[J]. 广西医学, 2008,30(11):1671-1672.
[4] 陈美玲 . 291例结直肠癌患者的临床病理分析[J]. 大家健康(学术版), 2015,9(8):66-67.
[5] 邱大胜, 胡晓燕, 彭辽河 , 等. 18F-FDG-PET/CT对结直肠癌术后血清CEA升高患者的诊断价值 [J]. 临床放射学杂志, 2013,32(12):1739-1742.
[6] 路晓雯, 刘林祥, 崔新建 , 等. 18F-FDG PET/CT对结直肠癌术后血清CEA升高病例的临床诊断价值 [J]. 泰山医学院学报, 2010,31(2):83-85.
[7] 潘睿. 中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[C], 2017.
[8] 黄利娟, 陈继贵, 刘丽 , 等. 结直肠癌患者血清肿瘤标志物水平与预后关系[J]. 中国公共卫生, 2011,27(5):563-566.
doi: 10.11847/zgggws-2011-27-05-16
[9] Van Cutsem E, Cervantes A, Adam R , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016,27(8):1386-1422.
[10] 王贵玉 . 结直肠癌NCCN、NICE及ESMO指南的对比分析和解读[J]. 中国癌症杂志, 2015,25(11):849-853.
[11] Schmoll HJ, Van Cutsem E, Stein A , et al. ESMO Consensus Guidelines for management of patients with colon and rectal can-cer. A personalized approach to clinical decision making[J]. Ann Oncol, 2012,23(10):2479-2516.
[12] Chan K, Welch S, Walker-Dilks C , et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer[J]. Clin Oncol (R Coll Radiol), 2012,24(4):232-249.
[13] 王晶晶, 陈康, 徐万菊 . 直肠癌患者手术前后血清CA199和CA242水平测定及预后评价[J]. 中华肿瘤防治杂志, 2009,14(21):1667-1668.
[14] 刘传, 清水汪, 王宁 , 等. 结直肠癌术前血清CEA、CA199表达水平与临床病理关系的研究[J]. 医学研究杂志, 2012,41(3):27-30.
[15] 周华胜, 梁光林 . 癌胚抗原测定在直肠癌手术前后及药物化疗过程中的追踪研究[J]. 河北医学, 2010,16(4):455-456.
[16] Lim YK, Kam MH, Eu KW . Carcinoembryonic antigen screening: how far should we go?[J]. Singapore Med J, 2009,50(9):862-865.
[17] 陈恺杰 . 3种血清肿瘤标志物在诊断大肠癌中的价值[J]. 广东医学院学报, 2005,23(4):384-385.
[18] 高志海, 田志军, 安燚 . 五种肿瘤标志物联合检测在胃和结直肠癌诊断及随访中的临床意义[J]. 医学综述, 2012,18(10):1595-1597.
[1] 季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238.
[2] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报（医学版）, 2026, 58(2): 239-243.
[3] 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250.
[4] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256.
[5] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265.
[6] 杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284.
[7] 王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报（医学版）, 2026, 58(2): 290-300.
[8] 刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报（医学版）, 2026, 58(2): 301-306.
[9] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404.
[10] 李斌, 梁寒. 机器人胃癌根治术：研究进展与实践挑战[J]. 北京大学学报（医学版）, 2026, 58(2): 416-422.
[11] 董海峰, 陈恒星, 张常华. 恶性肿瘤中蛋白质乳酸化修饰的研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 423-430.
[12] 李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报（医学版）, 2026, 58(1): 169-174.
[13] 高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报（医学版）, 2026, 58(1): 22-29.
[14] 向钊, 杨莉, 杨静. 非靶向代谢组学揭示原发性干燥综合征血小板减少患者血清差异代谢物及代谢通路[J]. 北京大学学报（医学版）, 2025, 57(6): 1042-1050.
[15] 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部